4.6 Article

Chronic obstructive pulmonary disease

期刊

NATURE REVIEWS DISEASE PRIMERS
卷 1, 期 -, 页码 -

出版社

NATURE PORTFOLIO
DOI: 10.1038/nrdp.2015.76

关键词

-

资金

  1. Aquinox Pharmaceuticals
  2. AstraZeneca
  3. Boehringer Ingelheim
  4. Chiesi
  5. Daiichi Sankyo
  6. Novartis
  7. Takeda
  8. Pfizer
  9. Sun Pharmaceuticals
  10. Medical Research Council
  11. Wellcome Trust
  12. Public Health England
  13. British Lung Foundation
  14. Merck
  15. GlaxoSmithKline
  16. Teva
  17. Johnson Johnson
  18. Vifor Pharma
  19. Aquinox Pharmaceuticals
  20. AstraZeneca
  21. Boehringer Ingelheim
  22. Chiesi
  23. Daiichi Sankyo
  24. Novartis
  25. Takeda
  26. Pfizer
  27. Sun Pharmaceuticals
  28. Medical Research Council
  29. Wellcome Trust
  30. Public Health England
  31. British Lung Foundation
  32. Merck
  33. GlaxoSmithKline
  34. Teva
  35. Johnson Johnson
  36. Vifor Pharma

向作者/读者索取更多资源

Chronic obstructive pulmonary disease (COPD) is a common disease with high global morbidity and mortality. COPD is characterized by poorly reversible airway obstruction, which is confirmed by spirometry, and includes obstruction of the small airways (chronic obstructive bronchiolitis) and emphysema, which lead to air trapping and shortness of breath in response to physical exertion. The most common risk factor for the development of COPD is cigarette smoking, but other environmental factors, such as exposure to indoor air pollutants-especially in developing countries-might influence COPD risk. Not all smokers develop COPD and the reasons for disease susceptibility in these individuals have not been fully elucidated. Although the mechanisms underlying COPD remain poorly understood, the disease is associated with chronic inflammation that is usually corticosteroid resistant. In addition, COPD involves accelerated ageing of the lungs and an abnormal repair mechanism that might be driven by oxidative stress. Acute exacerbations, which are mainly triggered by viral or bacterial infections, are important as they are linked to a poor prognosis. The mainstay of the management of stable disease is the use of inhaled long-acting bronchodilators, whereas corticosteroids are beneficial primarily in patients who have coexisting features of asthma, such as eosinophilic inflammation and more reversibility of airway obstruction. Apart from smoking cessation, no treatments reduce disease progression. More research is needed to better understand disease mechanisms and to develop new treatments that reduce disease activity and progression.-

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据